logo
Menu

We provide briefings on technologies to different public stakeholders, from those delivering care and research funders stimulating innovation, to policy makers and advisory bodies. Most, if not all of these briefings, will be publicly available on this website via the search window.

Innovation Observatory > Reports > Drugs > Peginesatide for anaemia in chronic kidney disease – first and second line

< Back

Peginesatide for anaemia in chronic kidney disease – first and second line

Drugs

Cardiovascular Disease and Vascular Surgery

June 2012


Peginesatide is intended as a substitute for currently available erythropoiesis stimulating agents in the treatment of anaemia in chronic kidney disease (CKD) patients on dialysis. If licensed, peginesatide may offer another treatment option for this patient group. It is administered less frequently than most currently available treatments and can be stored at room temperature for up to three months once dispensed. Peginesatide is a synthetic peptide mimetic of human erythropoietin that binds directly to the erythropoietin receptor on red blood cell precursors to stimulate red cell formation.
The UK whole population prevalence of stage 3-5 CKD is 4.9%, with an estimated age-standardised prevalence of 8.5% (10.6% in females and 5.8% in males). The prevalence of anaemia in people with CKD depends on the stage of kidney disease, and ranges from 1% in people with moderate decreases in glomerular filtration rate to 33% in people with established renal failure. An estimated 90,000-108,000 of the population in England and Wales have anaemia associated with CKD.

Current treatment options for anaemia in CKD include blood transfusions (not indicated for people with anaemia of CKD in whom kidney transplant is a treatment option), the correction of iron or folate deficiency, epoetins, darbepoetin, and methoxy polyethylene glycol-epoetin beta. Peginesatide has completed phase III clinical trials comparing its effect on haemoglobin concentration against treatment with epoetin alfa or darbepoetin alpha.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts